Please login to the form below

Not currently logged in
Email:
Password:

Pfizer to close six research centres

Pfizer is to close six research and development facilities in the UK and US as part of its recent acquisition of Wyeth
Pfizer is to close six research and development facilities in the UK and US as part of its recent acquisition of Wyeth.

The remaining 14 out of the original 20 facilities will be consolidated into five main campuses and nine specialised units.

R&D operations will be eliminated in Gosport and Slough/Taplow in the UK; Princeton, New Jersey; Chazy, Rouses Point and Plattsburgh, New York; and Sanford and Research Triangle Park, North Carolina in the US.

Activities will also be significantly reduced at Collegeville, Pennsylvania; Pearl River, New York; and St Louis, Missouri. In addition, Pfizer will consolidate R&D functions from its New London, Connecticut site to its nearby research facility in Groton.

The restructuring will focus Pfizer's research activities on three main areas of biotherapeutics, pharmatherapeutics and vaccines, supported by specialised units such as monoclonal antibody discovery and regenerative medicine.

The five main research sites include Sandwich in Kent (UK); Cambridge, Massachusetts; Groton, Connecticut; Pearl River, New York; and La Jolla, California.

A broad outline of the restructure was announced back in April, when Wyeth stated that it expected a workforce reduction of 15 per cent – approximately 19,000 positions – as a result of the merger.

10th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics